MicroRNA-206 induces G1 arrest in melanoma by inhibition of CDK4 and Cyclin D

Pigment Cell and Melanoma Research

Volumn 27, Issue 2, 2014, Pages 275-286

  Georgantas, Robert W ^a   Streicher, Katie ^a   Luo, Xiaobing ^a   Greenlees, Lydia ^a   Zhu, Wei ^a   Liu, Zheng ^a   Brohawn, Philip ^a   Morehouse, Christopher ^a   Higgs, Brandon W ^a   Richman, Laura ^a   Jallal, Bahija ^a   Yao, Yihong ^a   Ranade, Koustubh ^a  

^a MEDIMMUNE   (United States)

Author keywords

Cell cycle; Cell growth; G1 arrest; Invasion; MicroRNA; Migration

Indexed keywords

CELL CYCLE; CELL GROWTH; G1 ARREST; INVASION; MICRORNA; MIGRATION;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; BIOPSY; CARCINOGENESIS; CASPASE 3; CASPASE 7; CELL MOVEMENT; CELL PROLIFERATION; COMPUTATIONAL BIOLOGY; CYCLIN D; CYCLIN-DEPENDENT KINASE 4; ENZYME ACTIVATION; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MICRORNAS; MIDDLE AGED; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; PROTEIN BIOSYNTHESIS; SKIN NEOPLASMS; TISSUE DONORS;

EID: 84894030999     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12200     Document Type: Article

References (90)

1. Acunzo, M., Romano, G., Palmieri, D., Lagana, A., Garofalo, M., Balatti, V., Drusco, A., Chiariello, M., Nana-Sinkam, P., and Croce, C.M. (2013). Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2. Proc. Natl Acad. Sci. USA 110, 8573-8578.
2. Adams, B.D., Furneaux, H., and White, B.A. (2007). The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol. Endocrinol. 21, 1132-1147.
3. Asangani, I.A., Harms, P.W., Dodson, L. et al. (2012). Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget 3, 1011-1025.
4. Bemis, L.T., Chen, R., Amato, C.M., Classen, E.H., Robinson, S.E., Coffey, D.G., Erickson, P.F., Shellman, Y.G., and Robinson, W.A. (2008). MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res. 68, 1362-1368.
5. Boyerinas, B., Park, S.M., Hau, A., Murmann, A.E., and Peter, M.E. (2010). The role of let-7 in cell differentiation and cancer. Endocr. Relat. Cancer 17, F19-F36.
6. Braig, S., Mueller, D.W., Rothhammer, T., and Bosserhoff, A.-K. (2010). MicroRNA miR-196a is a central regulator of HOX-B7 and BMP4 expression in malignant melanoma. Cell. Mol. Life Sci. 67, 3535-3548.
7. Calin, G.A., Dumitru, C.D., Shimizu, M. et al. (2002). Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 99, 15524-15529.
8. Chapman, P.B., Einhorn, L.H., Meyers, M.L. et al. (1999). Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J. Clin. Oncol. 17, 2745-2751.
9. Chen, J., Feilotter, H.E., Pare, G.C., Zhang, X., Pemberton, J.G., Garady, C., Lai, D., Yang, X., and Tron, V.A. (2010). MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am. J. Pathol. 176, 2520-2529.
10. Chen, J., Zhang, X., Lentz, C., Abi-Daoud, M., Pare, G.C., Yang, X., Feilotter, H.E., and Tron, V.A. (2011). miR-193b regulates Mcl-1 in melanoma. Am. J. Pathol. 179, 2162-2168.
11. Chen, X., Yan, Q., Li, S., Zhou, L., Yang, H., Yang, Y., Liu, X., and Wan, X. (2012). Expression of the tumor suppressor miR-206 is associated with cellular proliferative inhibition and impairs invasion in ERalpha-positive endometrioid adenocarcinoma. Cancer Lett. 314, 41-53.
12. De Angelis, P., Fjell, B., Kravik, K., Haug, T., Tunheim, S., Reichelt, W., Beigi, M., Clausen, O., Galteland, E., and Stokke, T. (2004). Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil. Int. J. Oncol. 24, 1279-1288.
13. Dienstmann, R., and Tabernero, J. (2011). BRAF as a target for cancer therapy. Anti-Cancer Agents Med. Chem. 11, 285-295.
14. Dong, Q., Meng, P., Wang, T., Qin, W., Qin, W., Wang, F., Yuan, J., Chen, Z., Yang, A., and Wang, H. (2010). MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS ONE 5, e10147.
15. Felicetti, F., Errico, M.C., Bottero, L. et al. (2008a). The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res. 68, 2745-2754.
16. Felicetti, F., Errico, M.C., Segnalini, P., Mattia, G., and Carè, A. (2008b). MicroRNA-221 and -222 pathway controls melanoma progression. Expert Rev. Anticancer Ther. 8, 1759-1765.
17. Fu, X., Han, Y., Wu, Y., Zhu, X., Lu, X., Mao, F., Wang, X., He, X., Zhao, Y., and Zhao, Y. (2011). Prognostic role of microRNA-21 in various carcinomas: a systematic review and meta-analysis. Eur. J. Clin. Invest. 41, 1245-1253.
18. Georgantas, R.W., Hildreth, R., Morisot, S., Alder, J., Liu, C.G., Heimfeld, S., Calin, G.A., Croce, C.M., and Civin, C.I. (2007). CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc. Natl Acad. Sci. USA 104, 2750-2755.
19. Grignol, V., Fairchild, E.T., Zimmerer, J.M. et al. (2011). miR-21 and miR-155 are associated with mitotic activity and lesion depth of borderline melanocytic lesions. Br. J. Cancer 105, 1023-1029.
20. Guo, R., Wu, Q., Liu, F., and Wang, Y. (2011). Description of the CD133+ subpopulation of the human ovarian cancer cell line OVCAR3. Oncol. Rep. 25, 141-146.
21. He, L., He, X., Lim, L.P. et al. (2007). A microRNA component of the p53 tumour suppressor network. Nature 447, 1130-1134.
22. He, X.Y., Chen, J.X., Zhang, Z., Li, C.L., Peng, Q.L., and Peng, H.M. (2010). The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice. J. Cancer Res. Clin. Oncol. 136, 1023-1028.
23. Heakal, Y., Kester, M., and Savage, S. (2011). Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma. Ann. Pharmacother. 45, 1399-1405.
24. Holst, L.M., Kaczkowski, B., Glud, M., Futoma-Kazmierczak, E., Hansen, L.F., and Gniadecki, R. (2011). The microRNA molecular signature of atypic and common acquired melanocytic nevi: differential expression of miR-125b and let-7c. Exp. Dermatol. 20, 278-280.
25. Jackman, J., and O'Connor, P.M. (2001). Methods for synchronizing cells at specific stages of the cell cycle. Curr. Protoc. Cell Biol. Chapter, Unit 8.3.
26. Kaehler, K.C., Piel, S., Livingstone, E., Schilling, B., Hauschild, A., and Schadendorf, D. (2010). Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin. Oncol. 37, 485-498.
27. Kertesz, M., Iovino, N., Unnerstall, U., Gaul, U., and Segal, E. (2007). The role of site accessibility in microRNA target recognition. Nat. Genet. 39, 1278-1284.
28. Khodayari, N., Mohammed, K.A., Goldberg, E.P., and Nasreen, N. (2011). EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene. Cancer Gene Ther. 18, 806-816.
29. Kim, J.K., and Diehl, J.A. (2009). Nuclear cyclin D1: an oncogenic driver in human cancer. J. Cell. Physiol. 220, 292-296.
30. Kim, H.K., Lee, Y.S., Sivaprasad, U., Malhotra, A., and Dutta, A. (2006). Muscle-specific microRNA miR-206 promotes muscle differentiation. J. Cell Biol. 174, 677-687.
31. Kobayashi, A., Ohta, T., and Yamamoto, M. (2004). Unique function of the Nrf2-Keap1 pathway in the inducible expression of antioxidant and detoxifying enzymes. Methods Enzymol. 378, 273-286.
32. Kondo, N., Toyama, T., Sugiura, H., Fujii, Y., and Yamashita, H. (2008). miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer Res. 68, 5004-5008.
33. Labbaye, C., and Testa, U. (2012). The emerging role of MIR-146A in the control of hematopoiesis, immune function and cancer. J. Hematol. Oncol. 5, 13.
34. Lai, V.K., Ashraf, M., Jiang, S., and Haider, K. (2012). MicroRNA-143 is a critical regulator of cell cycle activity in stem cells with co-overexpression of Akt and angiopoietin-1 via transcriptional regulation of Erk5/cyclin D1 signaling. Cell Cycle 11, 767-777.
35. Lee, J.-M., and Johnson, J.A. (2004). An important role of Nrf2-ARE pathway in the cellular defense mechanism. J. Biochem. Mol. Biol. 37, 139-143.
36. Leite, K.R.M., Tomiyama, A., Reis, S.T., Sousa-Canavez, J.M., Sañudo, A., Camara-Lopes, L.H., and Srougi, M. (2011). MicroRNA expression profiles in the progression of prostate cancer-from high-grade prostate intraepithelial neoplasia to metastasis. Urol. Oncol. 31, 769-801.
37. Li, Z., Hu, S., Wang, J., Cai, J., Xiao, L., Yu, L., and Wang, Z. (2010). MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol. Oncol. 119, 125-130.
38. Li, N., Zhong, X., Lin, X. et al. (2012). Lin-28 homologue A (LIN28A) promotes cell cycle progression via regulation of cyclin-dependent kinase 2 (CDK2), cyclin D1 (CCND1), and cell division cycle 25 homolog A (CDC25A) expression in cancer. J. Biol. Chem. 287, 17386-17397.
39. Lin, S.L., Chang, D.C., Ying, S.Y., Leu, D., and Wu, D.T. (2010). MicroRNA miR-302 inhibits the tumorigenicity of human pluripotent stem cells by coordinate suppression of the CDK2 and CDK4/6 cell cycle pathways. Cancer Res. 70, 9473-9482.
40. Lodygin, D., Tarasov, V., Epanchintsev, A., Berking, C., Knyazeva, T., Körner, H., Knyazev, P., Diebold, J., and Hermeking, H. (2008). Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7, 2591-2600.
41. Lu, Z., Luo, R.Z., Peng, H., Huang, M., Nishmoto, A., Hunt, K.K., Helin, K., Liao, W.S.-L., and Yu, Y. (2006). E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer. Oncogene 25, 230-239.
42. Lyng, H., Landsverk, K., Kristiansen, E., Deangelis, P., Ree, A., Myklebost, O., Hovig, E., and Stokke, T. (2005). Response of malignant B lymphocytes to ionizing radiation: gene expression and genotype. Int. J. Cancer 115, 935-942.
43. MacKie, R.M., Hauschild, A., and Eggermont, A.M. (2009). Epidemiology of invasive cutaneous melanoma. Ann. Oncol. 20(Suppl 6), vi1-vi7.
44. Missiaglia, E., Shepherd, C.J., Patel, S. et al. (2010). MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas. Br. J. Cancer 102, 1769-1777.
45. Motohashi, H., and Yamamoto, M. (2004). Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol. Med. 10, 549-557.
46. Muller, D.W., and Bosserhoff, A.K. (2008). Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma. Oncogene 27, 6698-6706.
47. Muthusamy, V., Hobbs, C., Nogueira, C., Cordon-Cardo, C., McKee, P.H., Chin, L., and Bosenberg, M.W. (2006). Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosom. Cancer 45, 447-454.
48. Noguchi, S., Mori, T., Otsuka, Y., Yamada, N., Yasui, Y., Iwasaki, J., Kumazaki, M., Maruo, K., and Akao, Y. (2012). Anti-oncogenic microRNA-203 induces senescence by targeting E2F3 protein in human melanoma cells. J. Biol. Chem. 287, 11769-11777.
49. Oh, J.S., Kim, J.J., Byun, J.Y., and Kim, I.A. (2010). Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras. Int. J. Radiat. Oncol. Biol. Phys. 76, 5-8.
50. Pan, X., Wang, Z.X., and Wang, R. (2011). MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol. Ther. 10, 1224-1232.
51. Penna, E., Orso, F., Cimino, D. et al. (2011). microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J. 30, 1990-2007.
52. Peter, M.E. (2009). Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle 8, 843-852.
53. Pusapati, R.V., Weaks, R.L., Rounbehler, R.J., McArthur, M.J., and Johnson, D.G. (2010). E2F2 suppresses Myc-induced proliferation and tumorigenesis. Mol. Carcinog. 49, 152-156.
54. Rempel, R.E., Mori, S., Gasparetto, M. et al. (2009). A role for E2F activities in determining the fate of Myc-induced lymphomagenesis. PLoS Genet. 5, e1000640.
55. Ren, S., and Rollins, B.J. (2004). Cyclin C/cdk3 promotes Rb-dependent G0 exit. Cell 117, 239-251.
56. Roy, D., Arason, G., Chowdhury, B., Mitra, A., and Calaf, G. (2010). Profiling of cell cycle genes of breast cells exposed to etodolac. Oncol. Rep. 23, 1383-1391.
57. Sanchez-Beato, M., Sanchez, E., Garcia, J.F. et al. (2004). Abnormal PcG protein expression in Hodgkin's lymphoma. Relation with E2F6 and NFkappaB transcription factors. J. Pathol. 204, 528-537.
58. Scheibner, K.A., Teaboldt, B., Hauer, M.C. et al. (2012). MiR-27a functions as a tumor suppressor in acute leukemia by regulating 14-3-3theta. PLoS ONE 7, e50895.
59. Schultz, J., Lorenz, P., Gross, G., Ibrahim, S., and Kunz, M. (2008). MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res. 18, 549-557.
60. Segura, M.F., Belitskaya-Levy, I., Rose, A.E. et al. (2010). Melanoma MicroRNA signature predicts post-recurrence survival. Clin. Cancer Res. 16, 1577-1586.
61. Selcuklu, S.D., Donoghue, M.T., and Spillane, C. (2009). miR-21 as a key regulator of oncogenic processes. Biochem. Soc. Trans. 37, 918-925.
62. Shen, Q., Uray, I.P., Li, Y., Krisko, T.I., Strecker, T.E., Kim, H.-T., and Brown, P.H. (2008). The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene 27, 366-377.
63. Sherr, C.J., and Roberts, J.M. (1999). CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501-1512.
64. Song, G., Zhang, Y., and Wang, L. (2009). MicroRNA-206 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation. J. Biol. Chem. 284, 31921-31927.
65. Spizzo, R., Nicoloso, M.S., Croce, C.M., and Calin, G.A. (2009). SnapShot: microRNAs in cancer. Cell 137, 586-586.
66. Stark, M.S., Tyagi, S., Nancarrow, D.J., Boyle, G.M., Cook, A.L., Whiteman, D.C., Parsons, P.G., Schmidt, C., Sturm, R.A., and Hayward, N.K. (2010). Characterization of the melanoma miRNAome by deep sequencing. PLoS ONE 5, e9685.
67. Streicher, K.L., Zhu, W., Lehmann, K.P. et al. (2012). A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth. Oncogene 31, 1558-1570.
68. Surveillance Research Program N. (2009). SEER Stat Fact Sheets: Melanoma of the Skin.
69. Tang, W., Yu, F., Yao, H., Cui, X., Jiao, Y., Lin, L., Chen, J., Yin, D., Song, E., and Liu, Q. (2013). miR-27a regulates endothelial differentiation of breast cancer stem like cells. Oncogene. doi:10.1038/onc.2013.214 (in press).
70. Tashiro, E., Tsuchiya, A., and Imoto, M. (2007). Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci. 98, 629-635.
71. Valastyan, S., and Weinberg, R.A. (2010). miR-31: a crucial overseer of tumor metastasis and other emerging roles. Cell Cycle 9, 2124-2129.
72. Venkatesh, T., Nagashri, M.N., Swamy, S.S., Mohiyuddin, S.M., Gopinath, K.S., and Kumar, A. (2013). Primary microcephaly gene MCPH1 shows signatures of tumor suppressors and is regulated by miR-27a in oral squamous cell carcinoma. PLoS ONE 8, e54643.
73. Vickers, M.M., Bar, J., Gorn-Hondermann, I. et al. (2012). Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease. Clin. Exp. Metastasis 29, 123-132.
74. Wagner, J.D., Gordon, M.S., Chuang, T.Y., and Coleman, J.J. (2000). Current therapy of cutaneous melanoma. Plast. Reconstr. Surg. 105, 1774-1799; quiz 1800-1.
75. Wang, X., Ling, C., Bai, Y., and Zhao, J. (2011). MicroRNA-206 is associated with invasion and metastasis of lung cancer. Anat. Rec. (Hoboken) 294, 88-92.
76. Wang, R., Hu, Y., Song, G., Hao, C.J., Cui, Y., Xia, H.F., and Ma, X. (2012a). MiR-206 regulates neural cells proliferation and apoptosis via Otx2. Cell. Physiol. Biochem. 29, 381-390.
77. Wang, W., Zhao, L.J., Tan, Y.X., Ren, H., and Qi, Z.T. (2012b). MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis 33, 1113-1120.
78. Williams, A.E., Perry, M.M., Moschos, S.A., Larner-Svensson, H.M., and Lindsay, M.A. (2008). Role of miRNA-146a in the regulation of the innate immune response and cancer. Biochem. Soc. Trans. 36, 1211-1215.
79. Witzel, Ii., Koh, L.F., and Perkins, N.D. (2010). Regulation of cyclin D1 gene expression. Biochem. Soc. Trans. 38, 217-222.
80. Xiao, L., Cui, Y.H., Rao, J.N., Zou, T., Liu, L., Smith, A., Turner, D.J., Gorospe, M., and Wang, J.Y. (2011). Regulation of cyclin-dependent kinase 4 translation through CUG-binding protein 1 and microRNA-222 by polyamines. Mol. Biol. Cell 22, 3055-3069.
81. Xu, C., Liu, S., Fu, H., Li, S., Tie, Y., Zhu, J., Xing, R., Jin, Y., Sun, Z., and Zheng, X. (2010). MicroRNA-193b regulates proliferation, migration and invasion in human hepatocellular carcinoma cells. Eur. J. Cancer 46, 2828-2836.
82. Yan, D., Zhou, X., Chen, X., Hu, D.-N., Dong, X.D., Wang, J., Lu, F., Tu, L., and Qu, J. (2009). MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. Invest. Ophthalmol. Vis. Sci. 50, 1559-1565.
83. Yan, D., Dong, X.D., Chen, X., Yao, S., Wang, L., Wang, J., Wang, C., Hu, D.N., Qu, J., and Tu, L. (2012). Role of microRNA-182 in posterior uveal melanoma: regulation of tumor development through MITF, BCL2 and cyclin D2. PLoS ONE 7, e40967.
84. Yao, Y., Higgs, B.W., Morehouse, C. et al. (2008). Development of potential pharmacodynamic and diagnostic markers for anti-IFN-α monoclonal antibody trials in systemic lupus erythematosus. Hum. Genomics Proteomics 2009, 1-15.
85. Yoshimoto, N., Toyama, T., Takahashi, S., Sugiura, H., Endo, Y., Iwasa, M., Fujii, Y., and Yamashita, H. (2011). Distinct expressions of microRNAs that directly target estrogen receptor alpha in human breast cancer. Breast Cancer Res. Treat. 130, 331-339.
86. Zhang, T., Liu, M., Wang, C., Lin, C., Sun, Y., and Jin, D. (2011). Down-regulation of MiR-206 promotes proliferation and invasion of laryngeal cancer by regulating VEGF expression. Anticancer Res. 31, 3859-3863.
87. Zhang, D., Li, X., Chen, C. et al. (2012a). Attenuation of p38-mediated miR-1/133 expression facilitates myoblast proliferation during the early stage of muscle regeneration. PLoS ONE 7, e41478.
88. Zhang, W., Kong, G., Zhang, J., Wang, T., Ye, L., and Zhang, X. (2012b). MicroRNA-520b inhibits growth of hepatoma cells by targeting MEKK2 and cyclin D1. PLoS ONE 7, e31450.
89. Zhang, L., Liu, X., Jin, H. et al. (2013). miR-206 inhibits gastric cancer proliferation in part by repressing cyclinD2. Cancer Lett. 332, 94-101.
90. Zhou, J., Tian, Y., Li, J. et al. (2013). miR-206 is down-regulated in breast cancer and inhibits cell proliferation through the up-regulation of cyclinD2. Biochem. Biophys. Res. Commun. 433, 207-212.